NEW YORK – French synthetic biology firm Biomemory said on Tuesday that it has raised $18 million in Series A funding.

纽约——法国合成生物公司Biomemory周二表示，它已经在A系列融资中筹集了1800万美元。

The round was led by Crédit Mutuel Innovation, with participation from existing investor French Tech Seed fund and new investors Blast, the Deep Tech 2030 fund, Paris Business Angels, Sorbonne Venture, Adnexus, Prunay, Next Sequence, and Accelerem.

这一轮由Crédit Mutuel Innovation牵头，现有投资者法国科技种子基金和新投资者Blast、Deep Tech 2030基金、巴黎商业天使、索邦风险投资公司、Adnexus、Prunay、Next Sequence和Accelerem参与。

Biomemory plans to use the money to further develop and commercialize its DNA data storage technology, including forming partnerships with industry collaborators and cloud providers as well as recruiting R&D personnel.

Biomemory计划利用这笔资金进一步开发其DNA数据存储技术并将其商业化，包括与行业合作者和云提供商建立合作伙伴关系，以及招募研发人员。

The company plans to launch so-called DNA Cards for data storage and to scale its molecular data storage technology to exabytes for data center usage by 2030.

。

Based in Paris, Biomemory raised €5 million in seed funding in late 2022. The company is developing large-scale data storage technology using a proprietary enzymatic DNA synthesis technology.

总部位于巴黎的Biomemory于2022年末筹集了500万欧元的种子资金。该公司正在使用专有的酶促DNA合成技术开发大规模数据存储技术。

'This investment marks a pivotal moment for Biomemory and the future of data storage,' Biomemory Cofounder and CEO Erfane Arwani said in a statement. 'By sharing this value with our partners and collaborators, we aim to collectively advance the sector and foster a thriving data storage ecosystem.'

生物记忆联合创始人兼首席执行官埃尔凡·阿尔瓦尼（ErfaneArwani）在一份声明中说，这项投资标志着生物记忆和数据存储未来的关键时刻通过与我们的合作伙伴和合作者分享这一价值，我们的目标是共同推动该行业的发展，并培育一个蓬勃发展的数据存储生态系统。”